ACRSAclaris Therapeutics, Inc.
Price
+105%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market undecided.
Charts
As reported to the SEC, without any scoring.
Aclaris Therapeutics, Inc. (ACRS) reported revenue of $1.6M in Q2 2026 (quarter ended Jun 30, 2026), down 8.3% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $22M. For the full year FY2025, revenue was $7.8M (−58% year on year) and net income −$65M. Its largest product in Q2 2026 was Dermatology Therapeutics at $1.3M, 78% of the disclosed total, well ahead of Contract Research at 22%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”) under which the Company may offer and sell, from time to time at the Company’s sole …Material agreement entered · Form 8-K
- Aug 6, 2026Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update.Earnings release · press release
- May 7, 2026Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.6MThe company’s own SEC segment disclosure.
- Dermatology Therapeutics$1.3M78%
- Contract Research$356.0K22%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.